feed,title,long_url,short_url
Benzinga,"Roth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says ""Low Valuation Undeserved""",https://benzinga.com/general/biotech/23/09/34579967/roth-mkm-analyst-projects-an-impressive-price-target-of-15-over-the-next-12-months-for-biorestora,https://da.gd/14FFI3
